Capromorelin

Drug Profile

Capromorelin

Alternative Names: CP-424391; CP-424391-18; RQ-00000005; RQ-5

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma; Shire; University of Melbourne
  • Class Osteoporosis therapies; Pyrazolones; Small molecules
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal disorders; Musculoskeletal disorders

Highest Development Phases

  • No development reported Gastrointestinal disorders; Musculoskeletal disorders

Most Recent Events

  • 04 Sep 2015 No recent reports on development identified - Phase-I for Gastrointestinal disorders in USA, Australia (PO)
  • 16 Feb 2011 Carpromorelin licensed to Shire AG for the treatment of gastrointestinal disorders in the US
  • 17 Jan 2007 Phase-I clinical trials in Gastro-oesophageal reflux in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top